Breaking News, Collaborations & Alliances

Korsana Biosciences and Cyclerion Therapeutics to Merge, Operate Under Korsana Name

Korsana’s lead program is a next-generation shuttled antibody targeting amyloid beta for treatment of Alzheimer’s disease.

Author Image

By: Patrick Lavery

Content Marketing Editor

Korsana Biosciences and Cyclerion Therapeutics have reached a definitive merger agreement under which the combined company will take the Korsana name. An announcement of the pact on April 1, 2026 characterized it as an all-stock transaction. Official closing is coming in the third quarter of the year. Cyclerion, Korsana Histories Prior to Merger Previously, Cyclerion Therapeutics was a biopharmaceutical company focusing on treatments for neuropsychiatric diseases. Its foundational product ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters